CatalystFDA/Bio

Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug

Phase 3 trial failure triggers selloff, directly impacting drug approval prospects.

What changed

Phase 3 trial failure triggers selloff, directly impacting drug approval prospects.

Why it matters

Phase 3 trial failure triggers selloff, directly impacting drug approval prospects. — impact context not separately stored; see What changed.

Sources